Ian W Winter1, Timothy D Smile1, Gregory M M Videtic2. 1. Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, CA-5, Cleveland, OH, 44195, USA. 2. Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, CA-5, Cleveland, OH, 44195, USA. videtig@ccf.org.
Abstract
PURPOSE OF REVIEW: Patients with advanced cancer who have "oligometastatic" disease (OMD) have a limited burden of metastatic sites such that they may benefit from definitive therapies with limited toxicities. The incidence of cancers diagnosed in the elderly is increasing and treatment choices for them are often made because of their vulnerability to side effects. The present review discusses treatment of the elderly with OMD considering cancer outcomes and treatment toxicity. RECENT FINDINGS: Stereotactic body radiation therapy (SBRT) is emerging as a standard in the management of OMD because of its excellent local control and minimal toxicity. Phase II trials suggest that SBRT added to palliative therapy may improve overall survival and may delay the initiation of systemic therapy in OMD patients. Elderly patients are well represented in OMD studies SBRT will contribute significantly to the management of OMD in the elderly patient population by optimizing cancer control and limiting side effects.
PURPOSE OF REVIEW: Patients with advanced cancer who have "oligometastatic" disease (OMD) have a limited burden of metastatic sites such that they may benefit from definitive therapies with limited toxicities. The incidence of cancers diagnosed in the elderly is increasing and treatment choices for them are often made because of their vulnerability to side effects. The present review discusses treatment of the elderly with OMD considering cancer outcomes and treatment toxicity. RECENT FINDINGS: Stereotactic body radiation therapy (SBRT) is emerging as a standard in the management of OMD because of its excellent local control and minimal toxicity. Phase II trials suggest that SBRT added to palliative therapy may improve overall survival and may delay the initiation of systemic therapy in OMD patients. Elderly patients are well represented in OMD studies SBRT will contribute significantly to the management of OMD in the elderly patient population by optimizing cancer control and limiting side effects.
Authors: Benjamin Lacas; Jean Bourhis; Jens Overgaard; Qiang Zhang; Vincent Grégoire; Matthew Nankivell; Björn Zackrisson; Zbigniew Szutkowski; Rafał Suwiński; Michael Poulsen; Brian O'Sullivan; Renzo Corvò; Sarbani Ghosh Laskar; Carlo Fallai; Hideya Yamazaki; Werner Dobrowsky; Kwan Ho Cho; Beth Beadle; Johannes A Langendijk; Celia Maria Pais Viegas; John Hay; Mohamed Lotayef; Mahesh K B Parmar; Anne Aupérin; Carla van Herpen; Philippe Maingon; Andy M Trotti; Cai Grau; Jean-Pierre Pignon; Pierre Blanchard Journal: Lancet Oncol Date: 2017-07-27 Impact factor: 41.316
Authors: Anne Kaufmann; Heike Schmidt; Christian Ostheimer; Janine Ullrich; Margarete Landenberger; Dirk Vordermark Journal: Support Care Cancer Date: 2014-12-06 Impact factor: 3.603
Authors: Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz Journal: J Clin Oncol Date: 2009-04-29 Impact factor: 44.544